086900

MedyTox is a biopharmaceutical company focused on the research, development, manufacturing, and sale of botulinum toxin type A drugs and hyaluronic acid fillers. Its primary product, Meditoxin (marketed as Neuronox, Siax, Botulift, Cunox, and Meditoxin), is a liquid botulinum toxin type A formulation developed using proprietary technology. The company also produces Innotox, a non-animal-derived liquid botulinum toxin type A drug, and Coretox, a newer formulation. Its medical device portfolio includes the Neuramis series of hyaluronic acid fillers and the lipolytic injection Newbju. MedyTox manufactures its products in South Korea and is developing a production facility in the United Arab Emirates. It sells its products domestically and internationally through distributors and joint ventures. The company has established partnerships with Allergan for clinical trials of a novel botulinum toxin formulation and with Dubai Science Park for facility construction. MedyTox was founded in 2000 and is part of a group that includes subsidiaries such as NewmeCo, Potentfill, Neuraderm, and Kanui.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage medytox.com
Sector Healthcare IR page medytox.com
Tags
botulinum toxin, hyaluronic acid fillers, aesthetic medicine, neurotoxin, lipolytic injections, biopharmaceuticals, medical devices, Meditoxin, Neuronox, Siax, Botulift, Cunox, Innotox, Coretox, Neuramis, Newbju, NewmeCo, Potentfill, Neuraderm, Kanui, MedyTox Academy, MedyTox Business Center, MedyTox Venture Investment
Press page —

Metrics

Valuation  
Market cap ₩ 516.427B
Market cap (USD) $ 380.081M
P/E 31.14
PEG —
P/BV 1.38
P/S 2.06
P/OCF 7.55
P/FCF 9.49
Dividend yield —
Turnover / mcap —
Returns  
ROE 3.6%
ROI 3.7%
ROIC 3.8%
Profit margin 6.7%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -23.5%
Quality  
Profitable Yes
Margin expanding No
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 18.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 247.29B 228.622B 221.121B 195.096B 184.87B 140.828B 205.9B 205.445B 181.239B 133.256B 88.505B 75.892B 39.141B
Net profit 16.594B 16.955B 9.755B 37.01B 94.154B -29.577B 26.206B 69.964B 73.279B 59.231B 42.293B 43.628B 14.304B
Free cash flow 45.749B 27.83B 5.862B 16.304B 2.452B -13.217B 12.682B 46.572B 21.641B -82.398B -7.731B 88.744B 43.077M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 121.427K 118.631K — — — — — — — — — — —
Price performance 12m 0.02 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 31.4B 56B 67.4B 61.3B 42.9B 44.2B 53.9B 68.9B 58.4B 59.4B
↳ YoY growth +66.3% +78.6% +20.3% -9.0% -30.0% +3.2% +21.8% +27.9% -15.3% +1.8%
↳ 5y CAGR +43.8% +33.6% +17.9% +7.1% -0.8% +0.5% -1.0% +6.7%
Borrowings, current (KRW) 0.00 — — — — — 95.1B 61.1B 59.3B 56.6B
Borrowings, non-current (KRW) 61.8B — 0.00 0.00 28.2B — 20B 0.00 20B 18B
Bonds payable (KRW) — — 0.00 0.00 28.2B — 32B 0.00 0.00 —
Lease liabilities (KRW) — — — — — — 747M 1.75B 2.01B 2.01B
Cash and deposits (KRW) 15.8B 26.4B 19.2B 20B 44B 71.8B 20.7B 33.2B 46.2B 48.9B
Intangible assets (KRW) 19.3B 28.4B 21B 22.3B 18B 11.8B 26.5B 54.2B 72B 77.6B
Right-of-use assets (KRW) — 0.00 0.00 761M 873M 884M 743M 1.72B — —
Net debt (borrowings + leases - cash) (KRW) 46B — -19.2B -20B -15.8B — 95.2B 29.6B 35.1B 27.7B
Cash flow detail
Operating cash flow (KRW) 54.1B 59.7B 55.1B 33.7B 27.9B 20B 26.2B 13.5B 36.6B 61.4B
Purchases of property, plant and equipment (KRW) -136B -38B -8.5B -21B -41.1B -17.5B -9.9B -7.66B -8.73B -15.7B
Purchases of intangible assets (KRW) -8.17B -8.67B -3.52B -2.64B -3.16B -3.83B -15.2B -29.8B -10B -18.6B
Change in receivables (cash effect) (KRW) -10.4B — — — — 17.2B -13.9B -30.6B — —
Change in inventories (cash effect) (KRW) -1.17B -4.48B -9.84B -6.99B -12.3B 1.4B -19.5B -8.91B — —
Change in payables (cash effect) (KRW) 888M — — — — -8B 9.72B 31.6B — —
Dividends paid (cash effect) (KRW) -9.6B -11.1B -12.1B -4.33B -5.54B 0.00 -8.04B -8.42B -8.42B -8.92B
Share buybacks (cash effect) (KRW) -15.8B -16.9B 0.00 -14.6B -10.4B -8.13B -16.9B -2.97B -10.1B -13.2B
Interest paid (cash effect) (KRW) -911M -2.03B -1.87B -2.05B -2.58B -3.63B -2.41B -3.8B -4.33B -1.41B
Income taxes paid (cash effect) (KRW) -12B -7.46B -14.3B -16.7B 5.23B -18B -18.9B -13.5B -7.46B -6.82B
Share-based compensation (KRW) 459M 5.23B 4.82B 1.87B 4.12B 3.9B 1.81B 1.83B — —
Operating cash flow before change in receivables (KRW) 64.5B — — — — 2.77B 40.1B 44.1B — —
Free cash flow (OCF - PPE - intangibles) (KRW) -90.6B 13B 43B 10B -16.4B -1.38B 1.1B -23.9B 17.8B 27.2B
Income detail
Total comprehensive income (KRW) 59.2B 72.2B 67.8B 24.8B -32B 96.4B 51B 9.74B 15.8B 5.55B
Comprehensive income to owners (KRW) 59.2B 72.3B 68B 25.5B -31.8B 97.5B 50.2B 10.3B 17B 6.61B
Provision for credit losses (KRW) -167M 1.27B 3.16B 11.5B 14.4B 1.16B 4.87B 547M — —
Credit cost ratio (credit losses / average receivables) (%) 0.7% 2.9% 5.1% 17.9% 27.7% 2.7% 9.9% 0.9% — —
Reported May 15, 2017 Mar 30, 2020 Aug 13, 2021 Aug 14, 2020 Aug 13, 2021 Mar 21, 2024 Mar 20, 2025 Mar 20, 2025 Mar 20, 2025 Mar 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

중간(분기)배당락 Bull 0 Bear 0 Routine
[기재정정]현금ㆍ현물배당결정 Bull 0 Bear 0 Routine

Prompts

MedyTox (ticker 086900), listed in South Korea.

ETFs Holding MedyTox

ETF Weight in ETF Shares Market value As of
AVEE 0.02% 536 $ 28.129K Nov 16, 2026
DFAE 0.00% 3,984 $ 209.314K Nov 12, 2026
DFEV 0.00% 919 $ 48.283K Nov 12, 2026
DFAX 0.00% 3,432 $ 180.313K Nov 12, 2026
DFEM 0.00% 713 $ 37.46K Nov 12, 2026
AVEM 0.00% 2,082 $ 109.261K Nov 16, 2026